Megan Shaw

President & CEO

2023 - Current

Healthcare Startup Advisor, Consultant & Board Member

2018

Managing Director, Life Sciences

2021 - 2023

Innovation Works is the most active seed investor in the Greater Pittsburgh region; the Life Sciences group has to date invested $22M into 88 seed-stage startups, with a combined $1.7B in follow-on investment and 17 exits. Within life sciences I led strategy, sourced investments, managed the existing portfolio of companies and headed the new AlphaLab Health accelerator, which we launched in partnership with Allegheny Health Network in 2021. I was a Board Observer for 12 portfolio companies and worked closely with regional universities, nonprofits, investors and industry players.

Portfolio Executive, Life Sciences

2021 - 2021

I spent my first six months at Innovation Works as a Portfolio Executive for Innovation Work’s Life Sciences portfolio.

Senior Program Facilitator

2020 - 2021

I was recruited to lead projects in the $1.5B NIH-funded program to source, evaluate and scale technologies for innovation in SARS-CoV-2 diagnostic testing. I reviewed the technical feasibility, commercial potential, regulatory likelihood, and potential for large-scale manufacturing of applicants ranging from startups to Fortune 500 companies. For the most promising applicants, we provided product development, clinical, regulatory, and manufacturing support, positioning them for large federal investments to ramp up Covid testing capacity in the US. I also served on the Variant Task Force to evaluate how tests performed with the emerging viral variants and developed online playbooks for educators on how to stand up a testing program.

VP Marketing and Business Development

2014 - 2018

HemoSonics is a point-of-care diagnostics company that developed an innovative coagulation diagnostic providing fully automated, rapid viscoelastic testing for bleeding management. I headed the Commercial Leadership Team as we developed a superior product that met clinician needs at the point of care. I conducted customer and market research, developed the market requirements and go-to-market strategy, and drove the market development, product sequencing, and launch plans. In addition, I led communication of the overall vision of the company, including developing the company brand and website and creating the fundraising materials for multiple rounds. When the company was acquired (for a very successful return to investors) by a multinational in 2017, I was part of the deal team who negotiated the sale.

General Manager

2010 - 2014

I was Employee #1 at HemoSonics, a university spinout which was founded by biomedical engineering professors at UVA. I established and oversaw all non-engineering functions, building a stable infrastructure of grant accounting, financial procedures and controls, HR policies, and other operational aspects that served the company through product pivots, fundraising, and key C-Suite hires.

Engagement Manager

2008 - 2010

Fitzgerald was a boutique data analytics consulting firm. I served as both project and relationship manager for a Fortune 500 manufacturing client where we built an analytics department, infusing data-driven decision making into the commercial and financial teams.

Investment Associate

2007 - 2008

PurePay was a $100M private equity fund acquiring and consolidating payment technologies. I was part of the deal team for two transactions, helping lead due diligence, conduct market research and develop financial models.

Consultant, Special Projects Manager for the CEO

2005 - 2007

Acquired by Deloitte in 2013, Monitor Group was a top-tier strategy consulting firm with an affiliated private equity fund, Monitor Clipper Partners, where I spent my first year working on mid-market acquisitions. I was then selected by the CEO of this 1,800 person organization to manage high-profile projects including engaging with senior politicians and media figures both domestically and internationally.